Stockpolly
Search
Delisting risk
APRE · NASDAQ · Biotechnology

Aprea Therapeutics (APRE)

Develops oral DNA-damage-response inhibitors for biomarker-defined solid tumors.

$0.8205
Pre-market−0.02 (−2.86%)
At close$0.8447(+1.08%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue000100000000
Cost of revenue222332220000
Gross profit−2−2−1−2−2−2−2−20000
222221223334
Research & development222332222122
222221221222
General & administrative222221221222
Other expenses−2−2−2−3−3−2−2−20000
Operating income−4−4−3−4−4−3−4−3−3−3−3−4
000000000000
Interest income000000000000
Other non-operating income000000000000
Income before tax−3−3−3−3−4−3−4−3−3−2−3−4
Net income from continuing operations−3−3−3−3−4−3−4−3−3−2−3−4
Net income−3−3−3−3−4−3−4−3−3−2−3−4
EPS, basic−$0.86−$0.92−$0.67−$0.58−$0.64−$0.49−$0.66−$0.53−$0.47−$0.32−$0.43−$0.07
EPS, diluted−$0.86−$0.92−$0.67−$0.58−$0.64−$0.49−$0.66−$0.53−$0.47−$0.32−$0.43−$0.07
Weighted average shares, basic4446666668853
Weighted average shares, diluted4446666668853
EBITDA−4−3−3−3−4−3−4−3−3−2−3−4
Depreciation & amortization000000000000
EBIT−4−3−3−3−4−3−4−3−3−2−3−4